clinical trial risk
Clinical trials that fail, get delayed or need more studies, holding up a drug or device.
Exposure · 25 companies
ADRX ADARx Pharmaceuticals, Inc.
Exposed“Trials may be delayed, suspended or terminated because of safety signals, regulatory requests, manufacturing or protocol issues, limited enrollment, or CRO and site performance.”
APMD Apnimed, Inc.
Exposed“The company also cautions that trial results are preliminary and may not be replicated.”
ARMP Armata Pharmaceuticals, Inc.
Exposed“Trials may be delayed, enroll slowly, fail to complete, or require additional studies, increasing costs and postponing approval and revenue.”
- Revenue$4.9MYoY −5.2%
- Net income−$173.8Mvs −$18.9M year ago
- Revenue$3.2MYoY +173.6%
- Net income$54.9Mvs −$26.7M year ago
ASPE Aspen Neuroscience, Inc.
Exposed“The approach is novel, and its safety, efficacy, ability to slow or halt PD progression, and regulatory prospects are unproven.”
ATTO Attovia Therapeutics, Inc.
Exposed“Drug development is lengthy, costly and uncertain, and early findings may not predict later results.”
BLSM BlossomHill Therapeutics, Inc.
Exposed“Development is lengthy, costly, and uncertain: encouraging preclinical or early clinical results may not predict later outcomes, and delays, additional studies, trial changes, manufacturing issues, or regulatory disagreement could increase costs and allow competitors to advance first.”
BRVE Braveheart Bio, Inc.
Exposed“Trials can be delayed by enrollment and retention problems, dropouts, site or contractor performance, supply constraints, or additional regulatory requirements; negative or inconclusive results could prevent approval or restrict the indication or label.”
CAPR CAPRICOR THERAPEUTICS, INC.
Exposed“The FDA issued a Complete Response Letter in July 2025, citing insufficient substantial evidence of effectiveness and requesting additional clinical data.”
- Revenue$0vs $0 year ago
- Net income−$42.7MYoY −73.6%
CTY CITY THERAPEUTICS, INC.
Exposed“Early safety, knockdown or preclinical findings may not predict later results.”
EMI Encore Medical, Inc.
Exposed“Enrollment or trial delays, unfavorable results, or failure to obtain approval could prevent or delay U.S. commercialization.”
ETRA Electra Therapeutics, Inc.
Exposed“Ipsoprubart’s SURPASS trial is single-arm and open-label, studying treatment-naïve adults and children with sHLH.”
IAM Iambic Therapeutics, Inc.
Exposed“IAM has not demonstrated that it can obtain drug approval, and trials may be delayed, suspended or fail because of safety or efficacy results, recruitment and retention problems, regulatory or ethics review, CRO or site performance, inadequate funding, or manufacturing and supply issues.”
LTGO Latigo Biotherapeutics, Inc.
Exposed“Trial enrollment, CRO and site performance, data quality, safety findings, manufacturing availability, and regulatory review could delay or prevent approval.”
LYCA Lycia Therapeutics, Inc.
Exposed“Clinical success depends on showing efficacy and acceptable safety, recruiting and retaining participants, completing trials on time, obtaining regulatory clearance, and securing funding, IP protection, manufacturing, reimbursement and market acceptance.”
NUOX NuvOx Therapeutics, Inc.
Exposed“Trials may fail, reveal new safety issues, enroll slowly or require additional studies.”
PFE Pfizer
Exposed“Development is lengthy, costly and failure-prone: candidates may miss milestones, require additional trials, fail approval, receive restrictive labeling or prove less competitive than expected.”
- Revenue$62.6BYoY −1.6%
- Net income$7.8BYoY −3.2%
- Revenue$16.6BYoY −0.4%
- Net income$3.2BYoY −8.4%
REGN Regeneron Pharmaceuticals
Exposed“Clinical development is costly and uncertain: trials may fail to establish safety or efficacy, enroll adequately, or meet changing regulatory expectations.”
- Revenue$5.1BYoY +36.3%
- Net income$1.9BYoY +33.5%
SCTX Scribe Therapeutics, Inc.
Exposed“Safety and efficacy are uncertain, including risks of unintended on- or off-target effects, inadequate efficacy, immune responses and LNP-related liver toxicity.”
SDGR Schrödinger, Inc.
Exposed“Trial enrollment, safety, results, regulatory review, manufacturing, and commercial acceptance are uncertain;”
- Revenue$255.9MYoY +23.3%
- Net income−$103.3MYoY +44.8%
- Revenue$64.5MYoY +18.7%
- Net income−$37.7MYoY −15.0%
VOGX Vogenx, Inc.
Exposed“Trials may be delayed, inconclusive, or unsuccessful because of safety or efficacy findings, regulatory decisions, enrollment or retention difficulties, limited clinical-site capacity, contractor performance, manufacturing constraints, or inadequate funding.”
VRTX Vertex Pharmaceuticals
Exposed“More broadly, the success of Vertex’s clinical and preclinical programs, regulatory filings, development timelines, and research and development investments remains uncertain.”
- Revenue$3.4BYoY +11.8%
- Net income$653.6MYoY −39.6%
WWB WINDWARD BIO GROUP AG
Exposed“Trials may fail efficacy or safety endpoints, reveal adverse events, enroll slowly, or require additional studies.”
No companies have a recent 8-K matching these events.
No companies in the selected roles.